Results 31 to 40 of about 197,589 (314)

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer [PDF]

Clinical Cancer Research, 2017
Abstract Purpose: Resistance to anti-HER2 therapies in HER2+ breast cancer can occur through activation of alternative survival pathways or reactivation of the HER signaling network. Here we employed BT474 parental and treatment-resistant cell line models to investigate a mechanism by which HER2+ breast cancer can reactivate the HER ...
Xu X., De Angelis C., Burke K. A., Nardone A., Hu H., Qin L., Veeraraghavan J., Sethunath V., Heiser L. M., Wang N., Ng C. K. Y., Chen E. S., Renwick A., Wang T., Nanda S., Shea M., Mitchell T., Rajendran M., Waters I., Zabransky D. J., Scott K. L., Gutierrez C., Nagi C., Geyer F. C., Chamness G. C., Park B. H., Shaw C. A., Hilsenbeck S. G., Rimawi M. F., Gray J. W., Weigelt B., Reis-Filho J. S., Osborne C. K., Schiff R.   +33 more
openaire   +3 more sources

Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy [PDF]

, 2014
The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression of multiple RTKs which defines resistance to single ...
Goltsov, Alexey, Stylianos Kyriakidis, Hilal Khalil, Hu, Huizhong, Simon P. Langdon, Harrison, David James, Langdon, Simon P., Bown, James L., Khalil, Hilal S., Simon Langdon, Tero Soininen, Khalil, Hilal S, Soininen, Tero, Alexey Goltsov, Huizhong Hu, David J. Harrison, Bown, James, David Harrison, Deeni, Yusuf, Harrison, David J, Kyriakidis, Stylianos, Hu, Huizhong, Deeni, Yusuf Y.; id_orcid, Yusuf Deeni, Hilal S. Khalil, Langdon, Simon P, James Bown, Harrison, David J.   +27 more
core   +1 more source

Age-related Variation in Expression of Breast Cancer Tumour Markers in Iranian Patients [PDF]

Middle East Journal of Cancer, 2021
Background: There are believed to be several risk factors affecting the prognosis of breast cancer through their effect on the growth rate of tumour.
Fatemeh Homaei Shandiz, Fahimeh Afzaljavan, Amir Tajbakhsh, Maryam Rivadeh, Nourieh Sharifi, Mohammad Taghi Shakeri, Alireza Pasdar   +6 more
doaj   +1 more source

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab

Biomolecules, 2019
G309 or S310 mutations on the HER2 extracellular domain II induce receptor activation. Clinically, S310F is most frequent among HER2 extracellular domain mutations and patients with the S310F mutation without HER2 amplification responded to trastuzumab ...
Jung Won Shin, Soohyun Kim, Suji Ha, Byungsan Choi, Seongyeong Kim, Seock-Ah Im, Tae-Young Yoon, Junho Chung   +7 more
doaj   +1 more source

Salvage Mastectomy Is not the Treatment of Choice for Aggressive Subtypes of Ipsilateral Breast Cancer Recurrence: A Single-Institution Retrospective Study

European Journal of Breast Health, 2022
Objective:Patients with triple-negative (TN) or human epidermal growth factor 2 (HER2)-enriched ipsilateral breast cancer recurrence (IBCR) seem to be excluded from a second breast-conserving surgery (BCS) under the assumption that salvage mastectomy ...
Damiano Gentile, Andrea Sagona, Ruggero Spoto, Davide Franceschini, Stefano Vaccari, Valeriano Vinci, Ersilia Biondi, Lorenzo Scardina, Corrado Tinterri   +8 more
doaj   +1 more source

Epidemiological and pathological characteristics of postsurgical cases of invasive breast cancer among ethnicities of Iran in 2018: A single center cross-sectional study [PDF]

Archive of Oncology, 2020
Background: Present study aimed to investigate immunohistochemical parameters in post-surgical cases of invasive breast cancer. Methods: In this single center cross-sectional study we investigated ethnicity, familial history, type of cancer, stage of ...
Sayad Soheila, Yasin Ahmadi Seyyed Amir, Nekouian Reza, Panahi Mahshid, Anbari Khatereh   +4 more
doaj  

Targeting HER2 in breast cancer: new drugs and paradigms on the horizon

Exploration of Targeted Anti-tumor Therapy, 2021
About 15–20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification of ERBB2 gene.
Paolo Tarantino, Stefania Morganti, Giuseppe Curigliano   +2 more
doaj   +1 more source

Clinical characteristics and survival analysis of rare mutations in locally advanced or metastatic lung adenocarcinoma

陆军军医大学学报, 2022
Objective To analyze the efficacy and safety of different treatments in advanced lung adenocarcinoma patients with v-raf murine sarcoma viral oncogene homolog B1(BRAF) BRAF V600E mutation, human epidermal growth factor receptor 2 (HER2) mutation ...
LIN Qingyue, QU Jingjing, ZHOU Jianying
doaj   +1 more source

[Anti-HER2 vaccines: The HER2 immunotargeting future?].

Pathologie-biologie, 2009
Breast cancer is a widely spread women's disease. In spite of progress in the field of surgery and adjuvant therapies, the risk of breast cancer metastatic relapses remains high especially in those overexpressing HER2. Different studies have shown cellular and/or humoral immune responses against HER2 in patients with HER2-overexpressing tumors.
Ladjemi, Maha-Zohra, Jacot, William, Pèlegrin, André, Navarro-Teulon, Isabelle   +3 more
openaire   +2 more sources

HER2 overexpression is a putative diagnostic and prognostic biomarker for late-stage colorectal cancer in North African patients

Libyan Journal of Medicine, 2021
Aim: Colorectal cancer (CRC) is one of the leading cancers in the world. Even though its mortality and pathophysiology are well documented in the US and the European countries, it is seldom studied in North African population.
Eman A. Abdul Razzaq, Thenmozhi Venkatachalam, Khuloud Bajbouj, Mohamed Rahmani, Amena Mahdami, Surendra Rawat, Naziha Mansuri, Hussein Alhashemi, Rifat Akram Hamoudi, Riyad Bendardaf   +9 more
doaj   +1 more source